- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01625000
Safety and Efficacy of MP-214 in Patients With Schizophrenia
April 8, 2021 updated by: Mitsubishi Tanabe Pharma Corporation
A Double-Blind, Placebo-Controlled Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
512
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan
-
-
-
-
-
Seoul, Korea, Republic of
-
-
-
-
-
Taipei, Taiwan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent obtained from the patient before the initiation of any study-specific procedures
- Patients diagnosed with schizophrenia according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia
- Patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG)
Exclusion Criteria:
- Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder
The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
|
Experimental: MP-214 3mg
|
Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
|
Experimental: MP-214 6mg
|
Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.
|
Experimental: MP-214 9mg
|
Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.
|
Active Comparator: Risperidone 4mg
|
Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
Time Frame: Baseline and Week 6
|
PANSS score is a 30-item rating scale to assess both the positive and negative symptom syndromes of patients with schizophrenia.
Each item is scored on a 7-point scale, from 1 (absent) to 7 (extreme).
The PANSS total score of the 30 PANSS items ranges from 30 to 210.
High scores indicate greater severity of symptoms.
|
Baseline and Week 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Clinical Global Impression-Severity (CGI-S) Score at Week 6
Time Frame: Baseline and Week 6
|
CGI-S is a 7-point scale to assess the global severity of the participant's illness.
CGI-S scores range from 1 (normal, not ill at all) to 7 (extremely ill).
|
Baseline and Week 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
October 1, 2015
Study Registration Dates
First Submitted
June 19, 2012
First Submitted That Met QC Criteria
June 19, 2012
First Posted (Estimate)
June 21, 2012
Study Record Updates
Last Update Posted (Actual)
April 12, 2021
Last Update Submitted That Met QC Criteria
April 8, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Risperidone
Other Study ID Numbers
- A002-A4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on MP-214 3mg
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Mitsubishi Tanabe Pharma CorporationCompletedSchizophreniaTaiwan, Korea, Republic of, Japan
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
TakedaIntra-Cellular Therapies, Inc.TerminatedSchizophreniaUnited States
-
Nektar TherapeuticsCompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
AdAlta LimitedCompletedChronic Kidney Diseases | Interstitial Lung DiseaseAustralia
-
AdAlta LimitedCompletedInterstitial Lung DiseaseAustralia
-
Intra-Cellular Therapies, Inc.CompletedHeart Failure, SystolicUnited States
-
Intra-Cellular Therapies, Inc.CompletedParkinson DiseaseUnited States
-
Intra-Cellular Therapies, Inc.Laureate Institute for Brain Research, Inc.Completed